在刚果民主共和国以rVSV-ZEBOV-GP环接种疫苗应对埃博拉疫情

Jean-Jacques Muyembe¹, Hongchao Pan¹, Richard Peto¹+21

• ¹From the Institut National de Recherche Biomédicale and Faculté de Médecine, Université de Kinshasa (J.-J.M., P.M.-K., S.M., S.A.-M.), and the Ministry of Public Health (S.H.B.M., N.T., E.M.M.) - both in Kinshasa, Democratic Republic of Congo; the Nuffield Department of Population Health, University of Oxford, Oxford (H.P., R.P.), and the London School of Hygiene and Tropical Medicine, London (C.H.R., M.M.) - both in the United Kingdom; University of Florida, Gainesville (I.M.L.); and the World Health Organization, Geneva (A.D., A.T., G.E., P.-S.G., X.R.B., M.N.K.Y., A.S.G., I.-S.F., P.S., M.J.R., A.M.H.-R.).